Back to top
more

Clovis Oncology, Inc. (CLVS)

(Delayed Data from NSDQ)

$18.95 USD

18.95
1,240,915

+0.51 (2.77%)

Updated May 3, 2019 04:00 PM ET

After-Market: $18.96 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pfizer (PFE) Begins Dosing in Prostate Cancer Drugs Study

by Zacks Equity Research

Pfizer (PFE) is developing its oral PARP inhibitor, talazoparib (Talzenna), in combination with Xtandi as a potential treatment for castration-sensitive prostate cancer in a late-stage study.

Clovis (CLVS) Down 5.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Clovis Oncology (CLVS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Clovis (CLVS) delivered earnings and revenue surprises of 11.11% and -15.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Clovis (CLVS) Up 4.4% Since Last Earnings Report?

by Zacks Equity Research

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Radhika Saraogi headshot

Are Options Traders Betting on a Big Move in Clovis Oncology (CLVS) Stock?

by Radhika Saraogi

Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.

Clovis (CLVS) Stock Jumps 47.7%: Will It Continue to Soar?

by Zacks Equity Research

Clovis (CLVS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Clovis (CLVS) Q4 Earnings Miss, Revenues Beat, Stock Down

by Zacks Equity Research

Clovis (CLVS) reports wider-than-expected loss for fourth-quarter 2020. Sales of the company's sole marketed drug, Rubraca, increase year over year.

Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Alexion (ALXN) is set to provide updates on revenues and earnings when it releases fourth-quarter 2020 results on Feb 4.

Clovis (CLVS) Seeks Permission for Clinical Study on Novel Drug

by Zacks Equity Research

Clovis (CLVS) submits regulatory application to the FDA for initiating clinical study on its peptide-targeted radionuclide therapy, FAP-2286.

Company News for Dec 22, 2020

by Zacks Equity Research

Companies in the news are: LESL, RP, AJRD, CLVS

Clovis' (CLVS) Rubraca Confirmatory Study Meets Endpoint

by Zacks Equity Research

Clovis' (CLVS) Rubraca achieves significant improvement in progression free survival compared to chemotherapy in late-stage confirmatory study for BRCA-mutated ovarian cancer indication.

    Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock?

    by Zacks Equity Research

    Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.

    Clovis (CLVS) Up 18.6% Since Last Earnings Report: Can It Continue?

    by Zacks Equity Research

    Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Clovis (CLVS) Q3 Earnings Top, Sales Show Coronavirus Impact

    by Zacks Equity Research

    Clovis (CLVS) reports mixed third-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares plunge.

    Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Clovis (CLVS) delivered earnings and revenue surprises of 11.88% and -8.42%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

    Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know

    by Zacks Equity Research

    Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Glaxo's Zejula Gets Positive CHMP View for First-Line Setting

    by Zacks Equity Research

    The CHMP's favorable response recommends the regulatory nod for GlaxoSmithKline's (GSK) Zejula as the first-line maintenance treatment of ovarian cancer patients regardless of the biomarker status.

    Are Options Traders Betting on a Big Move in Clovis Oncology (CLVS) Stock?

    by Zacks Equity Research

    Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.

    Clovis (CLVS) Down 17.3% Since Last Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Clovis (CLVS) Q2 Earnings Lag, Revenues Show Coronavirus Impact

    by Zacks Equity Research

    Clovis (CLVS) reports dismal second-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares down.

    Clovis Oncology (CLVS) Reports Q2 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Clovis (CLVS) delivered earnings and revenue surprises of -8.82% and -10.67%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

    Clovis Oncology (CLVS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    by Zacks Equity Research

    Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Clovis (CLVS) Upgraded to Buy: Here's Why

    by Zacks Equity Research

    Clovis (CLVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    Is Clovis Oncology (CLVS) Stock a Solid Choice Right Now?

    by Zacks Equity Research

    Clovis Oncology (CLVS) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.